Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
NCT06274879Phase 2Recruiting
- Sponsor
- Insel Gruppe
- Start
- May 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in extrahepatic biliary tract cancer (ECC) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Grade 3 or 4 adverse events leading to systemic anti-tumor therapy discontinuation at 6 months. Started May 2026; status: recruiting.
02
Conditions
extrahepatic biliary tract cancer (ECC)
Beyond the preview
Go deeper on NCT06274879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274879.